Drawing for CEREVIA

USPTO serial 99870481

CEREVIA

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
SUTTON, CATHERINE ELIZABETH
Law office
TMEG LAW OFFICE 103

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with CEREVIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maurine Knutsson

Maurine Knutsson Knutsson IP ABNelinsgatan 14Norrkoping, 603 45Sweden

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment and prevention of cognitive disorders, sleep disorders, psychiatric diseases and disorders, viral infections and diseases, bacterial infections and diseases, allergies, opioid use disorder, and neurological diseases and disorders in the form of medicated nasal plugs and inserts; Biological preparations for the prevention and treatment of cognitive disorders, sleep disorders, psychiatric diseases and disorders, viral infections and diseases, bacterial infections and diseases, allergies, opioid use disorder, and neurological diseases and disorders in the form of medicated nasal plugs and inserts; Biologics in the nature of pharmaceutical preparations for the treatment of cognitive disorders, sleep disorders, psychiatric diseases and disorders, viral infections and diseases, bacterial infections and diseases, allergies, opioid use disorder, and neurological diseases and disorders in the form of medicated nasal plugs and inserts; Peptides for the treatment of cognitive disorders, sleep disorders, psychiatric diseases and disorders, viral infections and diseases, bacterial infections and diseases, allergies, opioid use disorder, and neurological diseases and disorders in the form of medicated nasal plugs and inserts; Drug delivery agents in the form of nasal plugs and inserts for the controlled release of drugs, nasal drug delivery devices, drug-eluting nasal plugs and inserts, medicated nasal inserts and plugs, controlled-release nasal delivery apparatus, nasal inserts and plugs pre-filled with pharmaceutical preparations, and nasal plugs and inserts for medical purposes that facilitate the delivery of pharmaceutical preparations that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations for reversing the effects of opioid overdoses; Pharmaceutical preparations in the form of medicated nasal insert and plug opioid receptor antagonists for the treatment of acute opioid overdoses; Central nervous system stimulantsACTIVE—
010Drug delivery devices sold empty, namely, nasal plugs and inserts for the controlled release of drugs, nasal drug delivery devices, drug-eluting nasal plugs and inserts, nasal inserts and plugs that can be medicated, and controlled-release nasal delivery apparatus; Drug delivery devices sold empty, namely, nasal plugs and inserts for medical purposes that facilitate the delivery of pharmaceutical preparations, nasal plugs and inserts for medical purposes that facilitate the delivery of biological preparations, nasal plugs and inserts for medical purposes that facilitate the delivery of biologics, and nasal plugs and inserts for medical purposes that facilitate the delivery of peptides; Drug delivery devices sold empty, namely, nasal inserts and plugs for filing with pharmaceutical preparations, nasal inserts and plugs for filing with biological preparations, nasal inserts and plugs for filing with biologics, and nasal inserts and plugs for filing with peptidesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 20, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 20, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Oct 20, 2026CNSLSUSPENSION LETTER WRITTEN—
Oct 16, 2026DOCKASSIGNED TO EXAMINER—
Oct 15, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 8, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 8, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance